Biofrontera Inc logo

Biofrontera Inc(BFRI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.7
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BFRI

11/13/2026: BFRI (1-star) is currently NOT-A-BUY. Pass it for now.

Biofrontera Inc is a micro-cap biopharmaceutical company specializing in commercializing prescription dermatology products and medical illumination lamps for sun-damaged skin and skin cancers. The company's primary strength lies in its flagship FDA-approved product, Ameluz, which has demonstrated robust double-digit revenue growth and high gross margins. Its main growth story centers on label expansion into new dermatological indications like superficial basal cell carcinoma and expanded device placements. However, investors face notable risks including historical operating losses, micro-cap share volatility, and single-product reliance. The stock suits risk-tolerant growth or momentum investors willing to monitor regulatory milestones and cash burn closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveExpanding product label approvals and strong double-digit revenue growth appeal to risk-tolerant growth strategies.
Momentum investorStrong fit while signal remains positiveShort-term price swings and news-driven volume surges offer trading opportunities conditional on positive technical upturn signals.
Value investorWeak fitOngoing net losses and negative earnings make traditional value metrics challenging to apply.
Dividend investorWeak fitThe company does not pay dividends and retains all cash for operational expansion.
Low-risk investorWeak fitHigh share price volatility and micro-cap biopharmaceutical risks conflict with conservative preservation strategies.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap status and clinical news flow trigger sharp fluctuations in share price.
Valuation riskMedium / highUncertainty surrounding future profitability makes traditional valuation support complex.
Competition risk (dermatology therapies)Medium / highIntense competition from established treatments and alternative photodynamic therapies can constrain market share gains.
Business qualityMediumProprietary FDA-approved products provide a defensible niche, though scale remains limited.
Dividend incomeLow / noneNo payouts are distributed to investors.
Execution riskHighSuccessful commercialization depends heavily on continuous clinical adoption and flawless regulatory execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.40M USD
Price to earnings Ratio -
1Y Target Price 6
Price to earnings Ratio -
1Y Target Price 6
Volume (30-day avg) 226.6K shares
Beta 0.96
52 Weeks Range 0.55 - 1.66
Updated Date 11/15/2026
52 Weeks Range 0.55 - 1.66
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.43

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -73.57%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BFRI receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
BFRI has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+40.7%) and solid revenue growth (+11.8%) are partially offset by weak cash generation (FCF margin -32.0%), weak profitability (net margin -25.3%).

Financial Health Rating

★★★★★
BFRI's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 21.7%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is BFRI's strongest growth driver at +40.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+11.8%, solid) is also solid, while free-cash-flow growth (-29.4%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 31.0% and approximately 69.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 11.99% supports management-shareholder alignment.

Top 5 Institutional Investors

Rosalind Advisors, Inc. 8.59%
AIGH Capital Management, LLC 4.98%
Renaissance Technologies Corp 4.45%
Acadian Asset Management LLC 1.11%
Citadel Advisors Llc 0.71%

Unit Economics (Per $1K Revenue)

★★★★★
BFRI generates approximately $787 of gross profit, $-219 of operating income, and $-320 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.24% (Tax Credit)

Quantitative Style Profile

★★★★★
BFRI has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Pharmaceutical Sales (Ameluz)Revenues generated from sales of the prescription topical gel Ameluz to wholesale distributors and dermatology practices.This is the primary revenue engine driving the company's financial results.
Medical Device Sales & Leasing (RhodoLED Lamps)Revenues generated from the sale and placement of specialized red-light illumination lamps required for photodynamic therapy.Device placements lock in recurring demand for the companion topical drug.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 13
Enterprise Value 13.24M
Price to Sales(TTM) 0.23
Enterprise Value 13.24M
Price to Sales(TTM) 0.23
Enterprise Value to Revenue 0.29
Enterprise Value to EBITDA -0.79
Shares Outstanding 14.85M
Shares Floating 10.32M
Shares Outstanding 14.85M
Shares Floating 10.32M
Percent Insiders 11.99
Percent Institutions 31.04

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.